메뉴 건너뛰기




Volumn 31, Issue 6, 2013, Pages 1573-1579

Multicenter phase II study of oxaliplatin and sorafenib in advanced gastric adenocarcinoma after failure of cisplatin and fluoropyrimidine treatment. A gemcad study

Author keywords

Advanced gastric adenocarcinoma; Antitarget therapies; Oxaliplatin; Second line treatment; Sorafenib

Indexed keywords

CISPLATIN; FLUOROPYRIMIDINE; OXALIPLATIN; SORAFENIB;

EID: 84888627652     PISSN: 01676997     EISSN: 15730646     Source Type: Journal    
DOI: 10.1007/s10637-013-0020-2     Document Type: Article
Times cited : (72)

References (32)
  • 2
    • 8044236424 scopus 로고    scopus 로고
    • Randomized comparison between chemotherapy plus best supportive care with best supportive care in advanced gastric cancer
    • 9093725 10.1023/A:1008243606668 1:STN:280:DyaK2s3kslGqug%3D%3D
    • Glimelius B, Ekstrom K, Hoffman K, Graf W, Sjoden PO et al (1997) Randomized comparison between chemotherapy plus best supportive care with best supportive care in advanced gastric cancer. Ann Oncol 8:163-168
    • (1997) Ann Oncol , vol.8 , pp. 163-168
    • Glimelius, B.1    Ekstrom, K.2    Hoffman, K.3    Graf, W.4    Sjoden, P.O.5
  • 3
    • 0028959887 scopus 로고
    • Randomised comparison of fluorouracil, epidoxorubicin and methotrexate (FEMTX) plus supportive care with supportive care alone in patients with non-resectable gastric cancer
    • 7533517 10.1038/bjc.1995.114 1:STN:280:DyaK2M7os1ertg%3D%3D
    • Pyrhonen S, Kuitunen T, Nyandoto P, Kouri M (1995) Randomised comparison of fluorouracil, epidoxorubicin and methotrexate (FEMTX) plus supportive care with supportive care alone in patients with non-resectable gastric cancer. Br J Cancer 71:587-591
    • (1995) Br J Cancer , vol.71 , pp. 587-591
    • Pyrhonen, S.1    Kuitunen, T.2    Nyandoto, P.3    Kouri, M.4
  • 4
    • 38749111139 scopus 로고    scopus 로고
    • Docetaxel monotherapy as a second-line treatment after failure of fluoropyrimidine and platinum in advanced gastric cancer: Experience of 154 patients with prognostic factor analysis
    • 18211985 10.1093/jjco/hym123
    • Jo JC, Lee JL, Ryu MH, Sym SJ, Lee SS et al (2007) Docetaxel monotherapy as a second-line treatment after failure of fluoropyrimidine and platinum in advanced gastric cancer: experience of 154 patients with prognostic factor analysis. Jpn J Clin Oncol 37:936-941
    • (2007) Jpn J Clin Oncol , vol.37 , pp. 936-941
    • Jo, J.C.1    Lee, J.L.2    Ryu, M.H.3    Sym, S.J.4    Lee, S.S.5
  • 5
    • 67449092163 scopus 로고    scopus 로고
    • Phase II study of paclitaxel combined with capecitabine as second-line treatment for advanced gastric carcinoma after failure of cisplatin-based regimens
    • 19123051 10.1007/s00280-008-0903-7 1:CAS:528:DC%2BD1MXmvV2ru7w%3D
    • Baize N, Abakar-Mahamat A, Mounier N, Berthier F, Caroli-Bosc FX (2009) Phase II study of paclitaxel combined with capecitabine as second-line treatment for advanced gastric carcinoma after failure of cisplatin-based regimens. Cancer Chemother Pharmacol 64:549-555
    • (2009) Cancer Chemother Pharmacol , vol.64 , pp. 549-555
    • Baize, N.1    Abakar-Mahamat, A.2    Mounier, N.3    Berthier, F.4    Caroli-Bosc, F.X.5
  • 6
    • 22944472396 scopus 로고    scopus 로고
    • Phase II study of docetaxel plus cisplatin as a second-line combined therapy in patients with advanced gastric carcinoma
    • 16080554 1:CAS:528:DC%2BD2MXpt1Wrt7o%3D
    • Kunisaki C, Imada T, Yamada R, Hatori S, Ono H et al (2005) Phase II study of docetaxel plus cisplatin as a second-line combined therapy in patients with advanced gastric carcinoma. Anticancer Res 25:2973-2977
    • (2005) Anticancer Res , vol.25 , pp. 2973-2977
    • Kunisaki, C.1    Imada, T.2    Yamada, R.3    Hatori, S.4    Ono, H.5
  • 7
    • 70849118953 scopus 로고    scopus 로고
    • Irinotecan plus capecitabine as a second-line treatment after failure of 5-fluorouracil and platinum in patients with advanced gastric cancer
    • 19797415 10.1093/jjco/hyp116
    • Sun Q, Hang M, Xu W, Mao W, Hang X et al (2009) Irinotecan plus capecitabine as a second-line treatment after failure of 5-fluorouracil and platinum in patients with advanced gastric cancer. Jpn J Clin Oncol 39:791-796
    • (2009) Jpn J Clin Oncol , vol.39 , pp. 791-796
    • Sun, Q.1    Hang, M.2    Xu, W.3    Mao, W.4    Hang, X.5
  • 8
    • 0034069620 scopus 로고    scopus 로고
    • Prospective randomized trial of docetaxel versus best supportive care in patients with non-small-cell lung cancer previously treated with platinum-based chemotherapy
    • 10811675 1:CAS:528:DC%2BD3cXktVyjsLc%3D
    • Shepherd FA, Dancey J, Ramlau R, Mattson K, Gralla R et al (2000) Prospective randomized trial of docetaxel versus best supportive care in patients with non-small-cell lung cancer previously treated with platinum-based chemotherapy. J Clin Oncol 18:2095-2103
    • (2000) J Clin Oncol , vol.18 , pp. 2095-2103
    • Shepherd, F.A.1    Dancey, J.2    Ramlau, R.3    Mattson, K.4    Gralla, R.5
  • 9
    • 22044445517 scopus 로고    scopus 로고
    • Erlotinib in previously treated non-small-cell lung cancer
    • 16014882 10.1056/NEJMoa050753 1:CAS:528:DC%2BD2MXmtFaksbo%3D
    • Shepherd FA, Rodrigues Pereira J, Ciuleanu T, Tan EH, Hirsh V et al (2005) Erlotinib in previously treated non-small-cell lung cancer. N Engl J Med 353:123-132
    • (2005) N Engl J Med , vol.353 , pp. 123-132
    • Shepherd, F.A.1    Rodrigues Pereira, J.2    Ciuleanu, T.3    Tan, E.H.4    Hirsh, V.5
  • 10
    • 2442661845 scopus 로고    scopus 로고
    • Randomized phase III trial of pemetrexed versus docetaxel in patients with non-small-cell lung cancer previously treated with chemotherapy
    • 15117980 10.1200/JCO.2004.08.163 1:CAS:528:DC%2BD2cXpsVWmurk%3D
    • Hanna N, Shepherd FA, Fossella FV, Pereira JR, De Marinis F et al (2004) Randomized phase III trial of pemetrexed versus docetaxel in patients with non-small-cell lung cancer previously treated with chemotherapy. J Clin Oncol 22:1589-1597
    • (2004) J Clin Oncol , vol.22 , pp. 1589-1597
    • Hanna, N.1    Shepherd, F.A.2    Fossella, F.V.3    Pereira, J.R.4    De Marinis, F.5
  • 11
    • 75149128685 scopus 로고    scopus 로고
    • Phase III trial of vinflunine plus best supportive care compared with best supportive care alone after a platinum-containing regimen in patients with advanced transitional cell carcinoma of the urothelial tract
    • 19687335 10.1200/JCO.2008.20.5534 1:CAS:528:DC%2BD1MXhtlCnsrfI
    • Bellmunt J, Theodore C, Demkov T, Komyakov B, Sengelov L et al (2009) Phase III trial of vinflunine plus best supportive care compared with best supportive care alone after a platinum-containing regimen in patients with advanced transitional cell carcinoma of the urothelial tract. J Clin Oncol 27:4454-4461
    • (2009) J Clin Oncol , vol.27 , pp. 4454-4461
    • Bellmunt, J.1    Theodore, C.2    Demkov, T.3    Komyakov, B.4    Sengelov, L.5
  • 12
    • 13544271958 scopus 로고    scopus 로고
    • Increased expression of mitogen-activated protein kinase and its upstream regulating signal in human gastric cancer
    • 15655810 1:CAS:528:DC%2BD2MXisVKjs7c%3D
    • Liang B, Wang S, Zhu XG, Yu YX, Cui ZR et al (2005) Increased expression of mitogen-activated protein kinase and its upstream regulating signal in human gastric cancer. World J Gastroenterol 11:623-628
    • (2005) World J Gastroenterol , vol.11 , pp. 623-628
    • Liang, B.1    Wang, S.2    Zhu, X.G.3    Yu, Y.X.4    Cui, Z.R.5
  • 13
    • 0036292971 scopus 로고    scopus 로고
    • Circulating VEGF levels in the serum of gastric cancer patients: Correlation with pathological variables, patient survival, and tumor surgery
    • 12131083 10.1097/00000658-200207000-00007
    • Karayiannakis AJ, Syrigos KN, Polychronidis A, Zbar A, Kouraklis G et al (2002) Circulating VEGF levels in the serum of gastric cancer patients: correlation with pathological variables, patient survival, and tumor surgery. Ann Surg 236:37-42
    • (2002) Ann Surg , vol.236 , pp. 37-42
    • Karayiannakis, A.J.1    Syrigos, K.N.2    Polychronidis, A.3    Zbar, A.4    Kouraklis, G.5
  • 14
    • 33644825389 scopus 로고    scopus 로고
    • Vascular endothelial growth factor-D and its receptor VEGFR-3: Two novel independent prognostic markers in gastric adenocarcinoma
    • 16344322 10.1200/JCO.2004.00.3467
    • Juttner S, Wissmann C, Jons T, Vieth M, Hertel J et al (2006) Vascular endothelial growth factor-D and its receptor VEGFR-3: two novel independent prognostic markers in gastric adenocarcinoma. J Clin Oncol 24:228-240
    • (2006) J Clin Oncol , vol.24 , pp. 228-240
    • Juttner, S.1    Wissmann, C.2    Jons, T.3    Vieth, M.4    Hertel, J.5
  • 15
    • 47949116252 scopus 로고    scopus 로고
    • Sorafenib in advanced hepatocellular carcinoma
    • 18650514 10.1056/NEJMoa0708857 1:CAS:528:DC%2BD1cXovFWjsL8%3D
    • Llovet JM, Ricci S, Mazzaferro V, Hilgard P, Gane E et al (2008) Sorafenib in advanced hepatocellular carcinoma. N Engl J Med 359:378-390
    • (2008) N Engl J Med , vol.359 , pp. 378-390
    • Llovet, J.M.1    Ricci, S.2    Mazzaferro, V.3    Hilgard, P.4    Gane, E.5
  • 16
    • 33846148701 scopus 로고    scopus 로고
    • Sorafenib in advanced clear-cell renal-cell carcinoma
    • 17215530 10.1056/NEJMoa060655 1:CAS:528:DC%2BD2sXksVKitg%3D%3D
    • Escudier B, Eisen T, Stadler WM, Szczylik C, Oudard S et al (2007) Sorafenib in advanced clear-cell renal-cell carcinoma. N Engl J Med 356:125-134
    • (2007) N Engl J Med , vol.356 , pp. 125-134
    • Escudier, B.1    Eisen, T.2    Stadler, W.M.3    Szczylik, C.4    Oudard, S.5
  • 17
    • 38049047178 scopus 로고    scopus 로고
    • Capecitabine and oxaliplatin for advanced esophagogastric cancer
    • 18172173 10.1056/NEJMoa073149 1:CAS:528:DC%2BD1cXisFSktg%3D%3D
    • Cunningham D, Starling N, Rao S, Iveson T, Nicolson M et al (2008) Capecitabine and oxaliplatin for advanced esophagogastric cancer. N Engl J Med 358:36-46
    • (2008) N Engl J Med , vol.358 , pp. 36-46
    • Cunningham, D.1    Starling, N.2    Rao, S.3    Iveson, T.4    Nicolson, M.5
  • 18
    • 0343247791 scopus 로고    scopus 로고
    • Oxaliplatin/cisplatin (L-OHP/CDDP) combination in heavily pretreated ovarian cancer
    • 9337681 10.1016/S0959-8049(97)00122-6 1:CAS:528:DyaK2sXmsVaisr8%3D
    • Soulie P, Bensmaine A, Garrino C, Chollet P, Brain E et al (1997) Oxaliplatin/cisplatin (L-OHP/CDDP) combination in heavily pretreated ovarian cancer. Eur J Cancer 33:1400-1406
    • (1997) Eur J Cancer , vol.33 , pp. 1400-1406
    • Soulie, P.1    Bensmaine, A.2    Garrino, C.3    Chollet, P.4    Brain, E.5
  • 19
    • 20944442210 scopus 로고    scopus 로고
    • Phase i trial of oxaliplatin in combination with cisplatin, protacted-infusion fluorouracil, and radiotherapy in advanced esophageal and gastroesophageal carcinoma
    • 15850907 10.1016/j.ijrobp.2004.09.009 1:CAS:528:DC%2BD2MXjsFKjsLo%3D
    • Maurel J, Cervantes A, Conill C, Salazar R, Martin-Richard M et al (2005) Phase I trial of oxaliplatin in combination with cisplatin, protacted-infusion fluorouracil, and radiotherapy in advanced esophageal and gastroesophageal carcinoma. Int J Radiat Oncol Biol Phys 62:91-96
    • (2005) Int J Radiat Oncol Biol Phys , vol.62 , pp. 91-96
    • Maurel, J.1    Cervantes, A.2    Conill, C.3    Salazar, R.4    Martin-Richard, M.5
  • 20
    • 32944478104 scopus 로고    scopus 로고
    • Results of a phase i trial of sorafenib (BAY 43-9006) in combination with oxaliplatin in patients with refractory solid tumors, including colorectal cancer
    • 16197622 10.3816/CCC.2005.n.030
    • Kupsch P, Henning BF, Passarge K, Richly H, Wiesemann K et al (2005) Results of a phase I trial of sorafenib (BAY 43-9006) in combination with oxaliplatin in patients with refractory solid tumors, including colorectal cancer. Clin Colorectal Cancer 5:188-196
    • (2005) Clin Colorectal Cancer , vol.5 , pp. 188-196
    • Kupsch, P.1    Henning, B.F.2    Passarge, K.3    Richly, H.4    Wiesemann, K.5
  • 21
    • 57849117384 scopus 로고    scopus 로고
    • New response evaluation criteria in solid tumours: Revised RECIST guideline (version 1.1)
    • 19097774 10.1016/j.ejca.2008.10.026 1:STN:280:DC%2BD1M%2Fgs12rug%3D%3D
    • Eisenhauer EA, Therasse P, Bogaerts J, Schwartz LH, Sargent D et al (2009) New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1). Eur J Cancer 45:228-247
    • (2009) Eur J Cancer , vol.45 , pp. 228-247
    • Eisenhauer, E.A.1    Therasse, P.2    Bogaerts, J.3    Schwartz, L.H.4    Sargent, D.5
  • 22
    • 0037352255 scopus 로고    scopus 로고
    • Phase II study of oxaliplatin, 5-fluorouracil and leucovorin in previously platinum-treated patients with advanced gastric cancer
    • 12598342 10.1093/annonc/mdg106 1:STN:280:DC%2BD3s%2Fos1Gmsw%3D%3D
    • Kim DY, Kim JH, Lee SH, Kim TY, Heo DS et al (2003) Phase II study of oxaliplatin, 5-fluorouracil and leucovorin in previously platinum-treated patients with advanced gastric cancer. Ann Oncol 14:383-387
    • (2003) Ann Oncol , vol.14 , pp. 383-387
    • Kim, D.Y.1    Kim, J.H.2    Lee, S.H.3    Kim, T.Y.4    Heo, D.S.5
  • 23
    • 59749091477 scopus 로고    scopus 로고
    • Chemotherapy, bevacizumab, and cetuximab in metastatic colorectal cancer
    • 19196673 10.1056/NEJMoa0808268 1:CAS:528:DC%2BD1MXhsFyitrw%3D
    • Tol J, Koopman M, Cats A, Rodenburg CJ, Creemers GJ et al (2009) Chemotherapy, bevacizumab, and cetuximab in metastatic colorectal cancer. N Engl J Med 360:563-572
    • (2009) N Engl J Med , vol.360 , pp. 563-572
    • Tol, J.1    Koopman, M.2    Cats, A.3    Rodenburg, C.J.4    Creemers, G.J.5
  • 24
    • 33847722573 scopus 로고    scopus 로고
    • Phase III trial of capecitabine plus oxaliplatin as adjuvant therapy for stage III colon cancer: A planned safety analysis in 1,864 patients
    • 17194911 10.1200/JCO.2006.08.1075 1:CAS:528:DC%2BD2sXht1ejs7g%3D
    • Schmoll HJ, Cartwright T, Tabernero J, Nowacki MP, Figer A et al (2007) Phase III trial of capecitabine plus oxaliplatin as adjuvant therapy for stage III colon cancer: a planned safety analysis in 1,864 patients. J Clin Oncol 25:102-109
    • (2007) J Clin Oncol , vol.25 , pp. 102-109
    • Schmoll, H.J.1    Cartwright, T.2    Tabernero, J.3    Nowacki, M.P.4    Figer, A.5
  • 25
    • 44849088035 scopus 로고    scopus 로고
    • Phase II study of combination chemotherapy of 5-fluorouracil, low-dose leucovorin, and oxaliplatin (FLOX regimen) in pretreated advanced gastric cancer
    • 18272910 10.1093/annonc/mdn013 1:STN:280:DC%2BD1czktlShsg%3D%3D
    • Jeong J, Jeung HC, Rha SY, Im CK, Shin SJ et al (2008) Phase II study of combination chemotherapy of 5-fluorouracil, low-dose leucovorin, and oxaliplatin (FLOX regimen) in pretreated advanced gastric cancer. Ann Oncol 19:1135-1140
    • (2008) Ann Oncol , vol.19 , pp. 1135-1140
    • Jeong, J.1    Jeung, H.C.2    Rha, S.Y.3    Im, C.K.4    Shin, S.J.5
  • 26
    • 84856524126 scopus 로고    scopus 로고
    • Phase i dose-finding study of sorafenib in combination with capecitabine and cisplatin as a first-line treatment in patients with advanced gastric cancer
    • 10.1007/s10637-010-9531-2 1:CAS:528:DC%2BC38XotVWgsA%3D%3D
    • Kim C, Lee JL, Choi YH, Kang BW, Ryu MH et al (2012) Phase I dose-finding study of sorafenib in combination with capecitabine and cisplatin as a first-line treatment in patients with advanced gastric cancer. Investig New Drugs 30:306-315
    • (2012) Investig New Drugs , vol.30 , pp. 306-315
    • Kim, C.1    Lee, J.L.2    Choi, Y.H.3    Kang, B.W.4    Ryu, M.H.5
  • 27
    • 77954574658 scopus 로고    scopus 로고
    • Phase II study of sorafenib in combination with docetaxel and cisplatin in the treatment of metastatic or advanced gastric and gastroesophageal junction adenocarcinoma: ECOG 5203
    • Sun W, Powell M, O'Dwyer PJ, Catalano P, Ansari RH, et al. Phase II study of sorafenib in combination with docetaxel and cisplatin in the treatment of metastatic or advanced gastric and gastroesophageal junction adenocarcinoma: ECOG 5203. J Clin Oncol 28:2947-2951
    • J Clin Oncol , vol.28 , pp. 2947-2951
    • Sun, W.1    Powell, M.2    O'Dwyer, P.J.3    Catalano, P.4    Ansari, R.H.5
  • 28
    • 80053573446 scopus 로고    scopus 로고
    • Bevacizumab in combination with chemotherapy as first-line therapy in advanced gastric cancer: A randomized, double-blind, placebo-controlled phase III study
    • Ohtsu A, Shah MA, Van Cutsem E, Rha SY, Sawaki A, et al. Bevacizumab in combination with chemotherapy as first-line therapy in advanced gastric cancer: a randomized, double-blind, placebo-controlled phase III study. J Clin Oncol 29:3968-3976
    • J Clin Oncol , vol.29 , pp. 3968-3976
    • Ohtsu, A.1    Shah, M.A.2    Van Cutsem, E.3    Rha, S.Y.4    Sawaki, A.5
  • 29
    • 85031963556 scopus 로고    scopus 로고
    • REGARD Phase 3, randomized trial of Ramucirumab in patinets with metastatic Gastric or GEj adenocarcinoma following progression on first. Ine chemotherapy
    • 10.1093/annonc/mdt201.1
    • Tabernero J (2013) REGARD Phase 3, randomized trial of Ramucirumab in patinets with metastatic Gastric or GEj adenocarcinoma following progression on first.ine chemotherapy. Ann Oncol 24:iv11-iv24
    • (2013) Ann Oncol , vol.24
    • Tabernero, J.1
  • 30
    • 80053341349 scopus 로고    scopus 로고
    • Survival advantage for irinotecan versus best supportive care as second-line chemotherapy in gastric cancer - A randomised phase III study of the Arbeitsgemeinschaft Internistische Onkologie (AIO)
    • Thuss-Patience PC, Kretzschmar A, Bichev D, Deist T, Hinke A, et al. Survival advantage for irinotecan versus best supportive care as second-line chemotherapy in gastric cancer - a randomised phase III study of the Arbeitsgemeinschaft Internistische Onkologie (AIO). Eur J Cancer 47:2306-2314
    • Eur J Cancer , vol.47 , pp. 2306-2314
    • Thuss-Patience, P.C.1    Kretzschmar, A.2    Bichev, D.3    Deist, T.4    Hinke, A.5
  • 31
    • 84862981823 scopus 로고    scopus 로고
    • Salvage Chemotherapy for Pretreated Gastric Cancer: A Randomized Phase III Trial Comparing Chemotherapy Plus Best Supportive Care with Best Supportive Care Alone
    • Kang JH, Lee SI, Lim do H, Park KW, Oh SY, et al. Salvage Chemotherapy for Pretreated Gastric Cancer: A Randomized Phase III Trial Comparing Chemotherapy Plus Best Supportive Care With Best Supportive Care Alone. J Clin Oncol 30:1513-1518
    • J Clin Oncol , vol.30 , pp. 1513-1518
    • Kang, J.H.1    Lee, S.I.2    Lim Do, H.3    Park, K.W.4    Oh, S.Y.5
  • 32
    • 80052246962 scopus 로고    scopus 로고
    • Survival predictors for second-line chemotherapy in Caucasian patients with metastatic gastric cancer
    • Bohanes P, Courvoisier DS, Perneger TV, Morel P, Huber O, et al. Survival predictors for second-line chemotherapy in Caucasian patients with metastatic gastric cancer. Swiss Med Wkly 141:w13249
    • Swiss Med Wkly , vol.141
    • Bohanes, P.1    Courvoisier, D.S.2    Perneger, T.V.3    Morel, P.4    Huber, O.5


* 이 정보는 Elsevier사의 SCOPUS DB에서 KISTI가 분석하여 추출한 것입니다.